Jiangsu Recbio Technology Co (HKSE:02179) ROCE % : -31.31% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Recbio Technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jiangsu Recbio Technology Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -31.31%.

Jiangsu Recbio Technology Co ROCE % Historical Data

The historical data trend for Jiangsu Recbio Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co ROCE % Chart

Jiangsu Recbio Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-15.19

-20.72

-43.92

-37.25

-29.69

Jiangsu Recbio Technology Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-36.70	-35.29	-35.25	-27.49	-31.31

Jiangsu Recbio Technology Co ROCE % Calculation

Jiangsu Recbio Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-611.288	/	( ( (2579.172 - 367.38)	+	(2391.304 - 485.895) )	/ 2 )
	=	-611.288	/	( (2211.792	+	1905.409)	/ 2 )
	=	-611.288	/	2058.6005
	=	-29.69 %

Jiangsu Recbio Technology Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-628.52	/	( ( (2455.822 - 345.814)	+	(2391.304 - 485.895) )	/ 2 )
	=	-628.52	/	( ( 2110.008	+	1905.409 )	/ 2 )
	=	-628.52	/	2007.7085
	=	-31.31 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Jiangsu Recbio Technology Co (HKSE:02179) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jiangsu Recbio Technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Recbio Technology Co (HKSE:02179) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN

Website

https://www.recbio.cn

Jiangsu Recbio Technology Co Ltd is an vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. Company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

Executives

Feng Tao	2201 Interest of corporation controlled by you
Bei Jing Jun Lian Cheng Yuan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Zhu Linan	2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Jun Cheng He Zhong Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Tian Jin Jun Lian Jie You Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Tian Jin Hui Zhi Yi Hao Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Chen Hao	2201 Interest of corporation controlled by you
La Sa Jun Qi Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Chao Rui Yi Yao Ke Ji He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Lyfe Capital Fund Iii (dragon), L.p.
Liu Yong
Chen Wei	2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si	2201 Interest of corporation controlled by you

Jiangsu Recbio Technology Co (HKSE:02179) Headlines

No Headlines